Bachleda, Petr; Utikal, Petr; Kalinova, Lucie; Köcher, Martin; Cerna, Marie; Kolar, Milan; Zadrazil, Josef
March 2010
Biomedical Papers of the Medical Faculty of Palacky University i;2010, Vol. 154 Issue 1, p13
Academic Journal
Background. Insufficient venous vasculature disallows autologous arteriovenous fistula creation. In this case an arteriovenous conduit of expanded polytetrafluoroethylene (ePTFE) interponed between artery and vein is used for hemodialysis. Although arteriovenous graft infection is an infrequent complication, infected grafts cannot be used for hemodialysis and can cause infection, sepsis and bleeding. Treatment options remain limited but the general approach is to maintain functional angioaccess and to eradicate infection. Aim. to summarize current knowledge of the prevention and treatment of arteriovenous graft infection. Methods. literature review Conclusions. ePTFE graft present an unreplaceable material used for angioaccess in patients with an insufficient venous vasculature. A number of risk factors causing graft infection is known. Since hemodialysis patients are a highrisk group, an effective strategies for graft infection prevention and early diagnosis should be determined. Among the most important risk factors belong surgical procedure, recurrent venipuncture and other infection disease. The prostheses should be removed when infected, especially in the presence of sepsis. In case of "localized infection", the prostheses can be removed partially only under the condition of careful patient selection and subsequent follow-up.


Related Articles

  • Determinants of type and timing of initial permanent hemodialysis vascular access. Stehman-Breen, Catherine O.; Sherrard, Donald J.; Gillen, Daniel; Caps, Michael // Kidney International;Feb2000, Vol. 57 Issue 2, p639 

    Determinants of type and timing of initial permanent hemodialysis vascular access. Background. We undertook a population-based study of hemodialysis (HD) patients to determine which factors are important in predicting the type of permanent access initially placed and if a functional permanent...

  • OCCULT ENDOGENOUS INFECTION WITHIN AN ARTERIAL PROSTHESIS. Thomford, Neil R.; DeLor, C. Joseph // Vascular Surgery;Nov/Dec1971, Vol. 5 Issue 5, p234 

    An occult infection confined to the inner surface of an aortic prosthesis resulted in recurrent septicemia over a period of two years and caused the patient's death. This unusual form of infection of an arterial prosthesis appeared to be endogenous in origin. Since sepsis complicated the early...

  • Woman who got HIV in transplant sues III. Hospital.  // Gay & Lesbian Times;11/26/2008, Issue 1092, p16 

    The article reports on a lawsuit filed by a 33-year old woman against the University of Chicago Medical Center and one of its doctor, claiming that she was infected with HIV and hepatitis C from a kidney transplant in January 9, 2007 from a donor who was found to have engaged in a male-to-male...

  • A 3-Year Follow-Up of Pre-Emptive vs Deferred Treatment of Cytomegalovirus Disease in Renal Transplantation. Brennan, D.C.; Schnitzler, M.A.; Metheney, T.G.; Rueda, J.F.; Woodward, R.S.; Lowell, J.A.; Singer, G.G.; Shenoy, S.; Howard, T.K.; Storch, G.A. // Clinical Drug Investigation;2000, Vol. 19 Issue 5, p367 

    Objective: To compare patient survival, graft survival and financial costs at 3 years after renal transplant in graft recipients who received pre-emptive or deferred treatment of cytomegalovirus (CMV) disease. Clinical outcomes and CMV-related charges at an average of 16 months' follow-up have...

  • Bleeding events and mortality in SCT patients: a retrospective study of hematopoietic SCT patients with organ dysfunctions due to severe sepsis or GVHD. Holler, E.; Kolb, H. J.; Greinix, H.; Perrotin, D.; Campilho, F.; Aversa, F.; Gil, L.; Cornelissen, J.; Varanese, L.; Schacht, A.; Friese, A.; Rustige, J. // Bone Marrow Transplantation;Mar2009, Vol. 43 Issue 6, p491 

    In autologous and allogeneic hematopoietic SCT (HSCT) neutropenia may be associated with severe infection. Immunodeficiency associated with GVHD and its treatment in allogeneic HSCT is also a risk for severe infection. In both periods, patients may develop severe sepsis with organ failure. To...

  • Abstracts, Italian Society of Nephrology.  // Kidney International;May1992, Vol. 41 Issue 5, p1439 

    Presents abstracts on nephrology discussed during the 32nd Congress of the Italian Society of Nephrology in Bologna, Italy. "Immunosuppressive Activity and Side Effects of Deflazacort Versus 6-methylprednisolone in Renal Transplantation," by A. Elli, R. Rivolta, and P. Palazzi; "Post-Biopsy...

  • Transmission of Human Immunodeficiency Virus by Transplantation of a Renal Allograft, with Development of the Acquired Immunodeficiency Syndrome. Kumar, Prem; Pearson, James E.; Martin, David H.; Leech, Stephen H.; Buisseret, Paul D.; Bezbak, Helen C.; Gonzalez, Francisco M.; Royer, John R.; Stretcher, H.Z.; Saxinger, W. Carl // Annals of Internal Medicine;Feb87, Vol. 106 Issue 2, p244 

    Presents a case study of HIV infection transmitted through kidney transplantation. Pre- and post-operative condition of the patient and donor; Possible mechanisms for the transmission of HIV infection; Recommendations.

  • Management of Cytomegalovirus Infection and Disease after Solid-Organ Transplantation. van der Bij, Wire; Speich, Rudolf // Clinical Infectious Diseases;7/1/2001 Supplement 1, Vol. 33, pS32 

    Discusses the considerable progress that has been made in elucidating risk factors for cytomegalovirus (CMV) infection in organ transplantation patients. Pathophysiology of CMV infection; Diagnosis; Prevention; Treatment.

  • Preemptive Therapy Versus Universal Prophylaxis with Ganciclovir for Cytomegalovirus in Solid Organ Transplant Recipients. Singh, Nina // Clinical Infectious Diseases;3/1/2001, Vol. 32 Issue 5, p742 

    Compares the effectiveness of preemptive therapy and universal prophylaxis with ganciclovir for treating cytomegalovirus in solid organ transplant recipients. Availability of preemptive therapy tools; Adverse effects of prophylaxis; Cost-effectiveness of the approaches.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics